Abstracts Archive - Page 965 of 2607 - ACR Meeting Abstracts

Abstract Number: 1929 • ACR Convergence 2020
Visual Ischemia During Relapse and Follow-up of Giant Cell Arteritis: A Systematic Review
Kubra Bugdayli¹, Patompong Ungprasert², Kenneth Warrington³ and Matthew J. Koster³, ¹Case Western Reserve University MetroHealth Medical Center, Cleveland, ²Cleveland Clinic Foundation, Cleveland, ³Mayo Clinic, Rochester, MN
Background/Purpose: The purpose of this study was to characterize the frequency of visual ischemia (VI) as a manifestation of relapse or during follow-up in patients…
Abstract Number: 1930 • ACR Convergence 2020
Thirty-Day Readmission Rate in Patients Who Were Initially Admitted for Active Giant Cell Arteritis
Shu Cao¹, Caroline Bresnan², Si Li³, Yichen Wang³ and Yih Chang Lin¹, ¹University of South Florida, Morsani College of Medicine, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, ³The Wright Center for Graduate Medical Education, Scranton
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with high potential for morbidity leading to frequent hospitalizations and significant economic burden to the…
Abstract Number: 1931 • ACR Convergence 2020
Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis
Naomi Serling-Boyd¹, Xiaoqing Fu², Yuqing Zhang³, Sebastian Unizony¹, Zachary Wallace⁴, Hyon Choi⁵ and John H. Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Giant cell arteritis (GCA) is a form of large vessel vasculitis that requires treatment with high-dose, long-term glucocorticoids (GC). Weight gain, among other side-effects…
Abstract Number: 1932 • ACR Convergence 2020
Giant Cell Arteritis – the Relationship Between the Extensiveness of Vasculitis and the Clinical Presentation
Alojzija Hocevar¹, Rok Jese¹, Matija Tomsic¹ and Ziga Rotar¹, ¹University Medical Center Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: Recent data show that the extensiveness of inflammation observed on colour Doppler ultrasonography (CDS) may indicate the risk for ocular ischaemia giant cell arteritis…
Abstract Number: 1933 • ACR Convergence 2020
Small Vessel Vasculitis Surrounding a Preserved Temporal Artery: Search for Tissue Biomarkers with Potential Diagnostic Value
Georgina Espígol-Frigolé¹, Roser Alba-Rovira², Salvador Naranjo-Suárez³, Magda Terenas⁴, Sergio Prieto-González¹, Marc Corbera-Bellalta³, Javier Marco-Hernández⁴, Marco A. Alba¹, Farah Kamberovic³, Roberto Ríos-Garcés¹, Jose Hernández-Rodríguez¹ and Maria C. Cid¹, ¹Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, ³IDIBAPS, Barcelona, Spain, ⁴Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose: Systemic vasculitides are complex and heterogeneous diseases with overlapping features that frequently pose a diagnostic challenge to clinicians. The temporal artery biopsy (TAB) is…
Abstract Number: 1934 • ACR Convergence 2020
What Is the Significance of Periarterial Temporal Small Vessel Inflammation (SVI) on Temporal Artery Biopsy (TAB) in the Diagnosis of Vasculitis? A Systematic Review and Meta-analysis
Elise Belilos¹, Steven Carsons² and Sonya Mehta¹, ¹NYU Winthrop Hospital, Mineola, NY, ²NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Isolated inflammation of small vessels including capillaries, venules and arterioles surrounding a normal temporal artery (SVI) in patients suspected of having giant cell arteritis…
Abstract Number: 1935 • ACR Convergence 2020
Predictors of Early Mortality for Giant Cell Arteritis at the Time of Diagnosis
Eduardo Dourado¹, Sofia Barreira², Ana Rita Cruz-Machado³, Joana Martinho³, Diana Raimundo⁴, Luísa Brites⁵, Helena Assunção⁵, Vítor Teixeira⁶, Nikita Khmelinskii³, Carla Macieira³, José A. P. da Silva⁷, João Eurico Fonseca⁸ and Cristina Ponte³, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ²Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ⁴Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal, ⁵Rheumatology Department, Centro Hospitalar Universitário Coimbra, Coimbra, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary systemic vasculitis, typically affecting patients aged > 50 years. If left untreated, GCA…
Abstract Number: 1936 • ACR Convergence 2020
Prospective Analysis of Flow Velocity of the Central Retinal Artery in Newly Diagnosed Patients with Giant Cell Arteritis with Visual Symptoms and Controls
Lara Burg¹, Katharina Reinking², Peter Brossart³, Robert Finger², Charlotte Behning⁴ and Valentin Schaefer⁵, ¹Clinic for Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Department of Ophthalmology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ³Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ⁴Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ⁵Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis in patients aged 50 years and older.1 Visual symptoms as amaurosis and…
Abstract Number: 1937 • ACR Convergence 2020
Aortic Aneurysm in Giant Cell Arteritis: A Nationwide Analysis
Jiayi Zheng¹, Ruoning Ni², Yan Tang³ and Liangjing Lu⁴, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ²St. Agnes Hospital, Baltimore, MD, ³Department of Stomatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory vasculopathy affecting primarily medium and large sized arteries. Previous studies have demonstrated a higher prevalence of aortic…
Abstract Number: 1938 • ACR Convergence 2020
Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis
Anne Bull Haaversen¹ and Andreas Diamantopoulos², ¹Martina Hansens Hospital, Hosle, Norway, ²Martina Hansens Hospital, Baerum, Norway
Background/Purpose: Giant cell arteritis (GCA) involves both the cranial and large vessels. Studies have shown that while the vision loss rates are higher, the relapse…
Abstract Number: 1939 • ACR Convergence 2020
Definitions and Reliability Assessment of Chronic Ultrasound Lesions of the Axillary Artery in Giant Cell Arteritis: A Study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
Valentin Schaefer¹, Stavros Chrysidis², Greta Carrara³, Wolfgang Schmidt⁴, George A. Bruyn⁵, Bhaskar Dasgupta⁶, Eugenio De Miguel⁷, Andreas Diamantopoulos⁸, Christina Duftner⁹, Ulrich Fredberg¹⁰, Berit Nielsen¹¹, Wolfgang Hartung¹², Alojzija Hocevar¹³, Annamaria Iagnocco¹⁴, Aaron Juche⁴, Tanaz Kermani¹⁵, Tove Lorenzen¹⁶, Pierluigi Macchioni¹⁷, Marcin Milchert¹⁸, Uffe Døhn¹⁹, Sara Monti²⁰, Chetan Mukhtyar²¹, Cristina Ponte²², Carlo Scire²³, Lene Terslev²⁴, Luca Seitz²⁵ and Christian Dejaco²⁶, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Sydvestjysk Sygehus Esbjerg, Esbjerg, Denmark, ³Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy, ⁴Immanuel Krankenhaus Berlin Buch, Berlin, Germany, ⁵Rheumatology, Reumakliniek Lelystad, Lelystad, Netherlands, ⁶Rheumatology, Mid and South Essex University Hospital NHS Foundation Trust, Southend University Hospital, United Kingdom, Westcliff on sea, England, United Kingdom, ⁷Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁸Martina Hansens Hospital, Baerum, Norway, ⁹Medical University Innsbruck, Innsbruck, Austria, ¹⁰Silkeborg Regional Hospital, Silkeborg, Denmark, ¹¹Aarhus University Hospital, Aarhus, Denmark, ¹²Asklepios Klinik Bad Abbach, Bad Abbacg, Germany, ¹³University Medical Center, Rheumatology, Ljubljana, LJUBLJANA, Slovenia, ¹⁴Università degli Studi di Torino, Academic Rheumatology Centre, Turin, Italy, ¹⁵David Geffen School of Medicine / University of California, Los Angeles, CA, ¹⁶Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ¹⁷Unità Operativa di Reumatologia/Arcispedale S. Maria Nuova, Reggio Emilia, Italy, ¹⁸Pomeranian Medical University, Szczecin, Poland, ¹⁹Center for Rheumatology and Spine Diseasesand COPECARE, Copenhagen, Denmark, ²⁰Fondazione IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy, ²¹Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom, ²²Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²³University of Ferrara, Ferrara, Italy, ²⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Copenhagen, Denmark, ²⁵Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ²⁶South Tyrol Health Trust, Hospital of Bruneck, Bruneck, Italy
Background/Purpose: The OMERACT Ultrasound (US) large vessel vasculitis task force has recently defined the US appearance of normal axillary arteries (AA) and the key elementary…
Abstract Number: 1940 • ACR Convergence 2020
In Newly Diagnosed Giant Cell Arteritis in a Real Life Setting Relapses Are Seen in More Than a Third of Patients – and Despite Faster Early Reduction High Cumulative Glucocorticoid Doses Are Reached
Laura Felten¹, Nicolai Leuchten¹ and Martin Aringer², ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany
Background/Purpose: To investigate real life glucocorticoid (GC) dosing and relapse rates in patients with new onset giant cell arteritis (GCA) in a single center.Methods: Complete…
Abstract Number: 1941 • ACR Convergence 2020
Outcome of Giant Cell Arteritis Patients Who Were Primarily Admitted for Venous Thromboembolism Events
Shu Cao¹, Caroline Bresnan², Si Li³, Yichen Wang³ and Yih Chang Lin¹, ¹University of South Florida, Morsani College of Medicine, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, ³The Wright Center for Graduate Medical Education, Scranton
Background/Purpose: Giant cell arteritis (GCA) has been shown to have an increased risk of developing deep venous thrombosis (DVT), pulmonary embolism (PE) and combined thromboembolism…
Abstract Number: 1942 • ACR Convergence 2020
Analysis of Vasculitis Patterns in Patients with Giant Cell Arteritis Compared to Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Lara Burg¹, Peter Brossart², Charlotte Behning³ and Valentin Schaefer⁴, ¹Clinic for Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ³Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ⁴Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) often coexist.1 The role of modern ultrasound (US) in diagnosis of GCA as well as PMR…
Abstract Number: 1943 • ACR Convergence 2020
The Prevalence of Anxiety and Depression in Patients with Giant Cell Arteritis
Joana Martinho¹, André Ponte², Eduardo Dourado³, Nikita Khmelinskii¹, Sara Dias⁴, Sofia Barreira⁵, Ana Rita Cruz-Machado¹, Carla Macieira¹, Vítor Teixeira⁶, Ana Rodrigues⁴, Diogo Telles-Correia⁷, João Eurico Fonseca⁸ and Cristina Ponte¹, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ⁴EpiDoC Unit, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa (NMS/UNL), Lisbon, Portugal, ⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷Serviço de Psiquiatria, Hospital de Santa Maria, CHULN, Lisboa, Portugal, Lisbon, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis of the elderly causing blindness if left untreated. However, its hallmark treatment with glucocorticoids…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].